OpenAI's new biology AI refuses less on dual-use science — vetted labs only

OpenAI released GPT-Rosalind-6 on October 30, a frontier reasoning model for biology, drug discovery and translational medicine, available only to approved scientists, research institutes, companies and government partners through its trusted-access program — not in the ordinary ChatGPT chat tab.

The twist is in the deployment, not the weights: Rosalind-6 runs on the same weights as GPT-6 Astra with no additional training, but with fewer refusals on dual-use biological queries, while still refusing requests for biological weaponization, and with a stricter cyber boundary.

On OpenAI's own benchmarks it roughly doubled its predecessor — 49.6% versus 28.9% on medicinal chemistry and 61.3% versus 44.0% on applied life sciences — and the company rates it High for biological and chemical capability, below its Critical threshold, with applicants screened on research plans, governance and security controls.